Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

Gene Therapy

Volumn 9, Issue 6, 2002, Pages 381-389

  Wang, Lijun ^a   Muramatsu, Shin Ichi ^a   Lu, Yanyan ^a   Ikeguchi, Kunihiko ^a   Fujimoto, Kenichi ^a   Okada, Takashi ^a   Mizukami, Hiroaki ^a   Hanazono, Yutaka ^a   Kume, Akihiro ^a   Urano, Fumi ^b   Ichinose, Hiroshi ^b   Nagatsu, Toshiharu ^b   Nakano, Imaharu ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Adeno associated virus; Gene therapy; Glial cell line derived neurotrophic factor; Neuroprotection; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CHOLERA TOXIN B SUBUNIT; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; PEPTIDE; TRACER; TYROSINE 3 MONOOXYGENASE;

ANATOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CELL LABELING; CONTROLLED STUDY; DENSITY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RETROGRADE NERVE FIBER TRANSPORT; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DEPENDOVIRUS; DISEASE PROGRESSION; DOPAMINE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS; MALE; MODELS, ANIMAL; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TIME FACTORS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 85047698430     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301682     Document Type: Article

References (41)

1. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
2. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
3. Parkinson's disease: A neurodegenerative disease particularly amenable to gene therapy
4. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors
5. Dopaminergic neurons protected from degeneration by GDNF gene therapy
6. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
7. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
8. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor
9. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease
10. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
11. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
12. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
13. Double immunocytochemistry for the detection of Fos protein in retrogradely identified neurons using cholera toxin B subunit
14. AAV vectors: Is clinical success on the horizon?
15. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
16. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase aromatic-L-amino-acid decarboxylase and GTP cyclohydrolase I for gene therapy of Parkinson's disease
17. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat
18. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats
19. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: An in situ hybridization study
20. Ageing and Parkinson's disease: Substantia nigra regional selectivity
21. A mathematical model of pathogenesis in idiopathic parkinsonism
22. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections
23. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat
24. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease
25. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration
26. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting, but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model
27. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector
28. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
29. Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression
30. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes
31. Differential expression of mRNAs of GDNF family in the striatum following 6-OHDA-induced lesion
32. Recombinant adeno-associated virus vector: Use for transgene expression and anterograde tract tracing in the CNS
33. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration
34. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease
35. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons
36. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons
37. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
38. Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro
39. Cloning and structural organization of the gene encoding the mouse glial cell line-derived neurotrophic factor, GDNF
40. Adeno-associated virus vectors can be efficiently produced without helper virus
41. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons